m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00003)
Regulator Name Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
Synonyms
hnRNP C1/C2; HNRPC
    Click to Show/Hide
Gene Name HNRNPC
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A)
KH-CB19 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for KH-CB19. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of KH-CB19 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [2]
leucettine L41 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for leucettine L41. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of leucettine L41 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [3]
ML315 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for ML315. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ML315 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [4]
WO2013026806C72 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) is a therapeutic target for WO2013026806C72 . The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of WO2013026806C72 through regulating the expression of Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A). [1], [3]
Extracellular matrix receptor III (CD44)
A-6 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for A-6. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of A-6 through regulating the expression of Extracellular matrix receptor III (CD44). [5], [6]
SPL-108 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for SPL-108. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of SPL-108 through regulating the expression of Extracellular matrix receptor III (CD44). [5], [7]
BIWA 4 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for BIWA 4. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of BIWA 4 through regulating the expression of Extracellular matrix receptor III (CD44). [5], [8]
Bivatuzumab mertansine [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Extracellular matrix receptor III (CD44) is a therapeutic target for Bivatuzumab mertansine. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Bivatuzumab mertansine through regulating the expression of Extracellular matrix receptor III (CD44). [5], [9]
Hepatitis A virus cellular receptor 2 (TIM3)
MBG453 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for MBG453. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of MBG453 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [10]
BGB-A425 [Phase 1/2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for BGB-A425. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of BGB-A425 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [11]
GSK4069889 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for GSK4069889. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of GSK4069889 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [12]
RO7121661 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for RO7121661. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of RO7121661 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [12]
INCAGN2390 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for INCAGN2390. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of INCAGN2390 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [13]
LY3321367 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3321367. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of LY3321367 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [14]
LY3415244 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for LY3415244. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of LY3415244 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [15]
Sym023 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Hepatitis A virus cellular receptor 2 (TIM3) is a therapeutic target for Sym023. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Sym023 through regulating the expression of Hepatitis A virus cellular receptor 2 (TIM3). [5], [16]
Interferon-beta (IFNB1)
Interferon beta-1a [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for Interferon beta-1a. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Interferon beta-1a through regulating the expression of Interferon-beta (IFNB1). [17], [18]
PEGylated IFN beta 1-a [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for PEGylated IFN beta 1-a. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of PEGylated IFN beta 1-a through regulating the expression of Interferon-beta (IFNB1). [17], [19]
PLEGRIDY [Approved]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for PLEGRIDY. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of PLEGRIDY through regulating the expression of Interferon-beta (IFNB1). [17], [20]
Biferonex [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for Biferonex. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Biferonex through regulating the expression of Interferon-beta (IFNB1). [17], [21]
FP-1201 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for FP-1201. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of FP-1201 through regulating the expression of Interferon-beta (IFNB1). [17], [22]
NU-100 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for NU-100. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of NU-100 through regulating the expression of Interferon-beta (IFNB1). [17], [23]
AZ-01, PEGylated interferon-beta [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for AZ-01, PEGylated interferon-beta. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of AZ-01, PEGylated interferon-beta through regulating the expression of Interferon-beta (IFNB1). [17], [24]
Interferon beta 1a [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for Interferon beta 1a. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Interferon beta 1a through regulating the expression of Interferon-beta (IFNB1). [17], [25]
PF-06823859 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for PF-06823859. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of PF-06823859 through regulating the expression of Interferon-beta (IFNB1). [17], [25]
ARX-424 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for ARX-424. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ARX-424 through regulating the expression of Interferon-beta (IFNB1). [17], [26]
Gene therapy, IFN-b [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for Gene therapy, IFN-b. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Gene therapy, IFN-b through regulating the expression of Interferon-beta (IFNB1). [17], [27]
TV-1390 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for TV-1390. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of TV-1390 through regulating the expression of Interferon-beta (IFNB1). [17], [25]
Maxy-10 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Interferon-beta (IFNB1) is a therapeutic target for Maxy-10. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Maxy-10 through regulating the expression of Interferon-beta (IFNB1). [17], [28]
Leukocyte common antigen (PTPRC)
131I-labelled aCD45 [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for 131I-labelled aCD45. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of 131I-labelled aCD45 through regulating the expression of Leukocyte common antigen (PTPRC). [5], [29]
Iomab-B [Phase 3]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Iomab-B. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Iomab-B through regulating the expression of Leukocyte common antigen (PTPRC). [5], [30]
[131I]-BC8 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for [131I]-BC8. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of [131I]-BC8 through regulating the expression of Leukocyte common antigen (PTPRC). [5], [31]
Anti-CD45 mabs [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Anti-CD45 mabs. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Anti-CD45 mabs through regulating the expression of Leukocyte common antigen (PTPRC). [5], [32]
Iomab-ACT [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Iomab-ACT. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Iomab-ACT through regulating the expression of Leukocyte common antigen (PTPRC). [5], [33]
LM-CD45 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for LM-CD45. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of LM-CD45 through regulating the expression of Leukocyte common antigen (PTPRC). [5], [34]
Asp-BrPmp-Leu [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for Asp-BrPmp-Leu. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Asp-BrPmp-Leu through regulating the expression of Leukocyte common antigen (PTPRC). [5], [35]
OX-30 [Terminated]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Leukocyte common antigen (PTPRC) is a therapeutic target for OX-30. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of OX-30 through regulating the expression of Leukocyte common antigen (PTPRC). [5], [36]
MAPK/ERK kinase kinase 3 (MAP3K3)
ISIS 122970 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122970. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122970 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122971 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122971. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122971 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122974 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122974. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122974 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122975 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122975. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122975 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122976 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122976. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122976 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122984 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122984. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122984 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122985 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122985. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122985 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122986 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122990 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122990. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122990 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [37]
ISIS 122991 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122991. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122991 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [38]
SRSF protein kinase 1 (SRPK1)
SPHINX31 [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary SRSF protein kinase 1 (SRPK1) is a therapeutic target for SPHINX31. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of SPHINX31 through regulating the expression of SRSF protein kinase 1 (SRPK1). [1], [39]
Superoxide dismutase Mn (SOD Mn)
Imisopasem manganese [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Superoxide dismutase Mn (SOD Mn) is a therapeutic target for Imisopasem manganese. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Imisopasem manganese through regulating the expression of Superoxide dismutase Mn (SOD Mn). [40], [41]
Vacuolar-type proton ATPase catalytic A (v-ATPase-A)
Cruentaren [Preclinical]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Vacuolar-type proton ATPase catalytic A (v-ATPase-A) is a therapeutic target for Cruentaren. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of Cruentaren through regulating the expression of Vacuolar-type proton ATPase catalytic A (v-ATPase-A). [1], [42]
References
Ref 1 N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015 Feb 26;518(7540):560-4. doi: 10.1038/nature14234.
Ref 2 Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. doi: 10.1021/jm200274d. Epub 2011 May 26.
Ref 3 Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3654-61. doi: 10.1016/j.bmcl.2013.02.096. Epub 2013 Mar 30.
Ref 4 Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3. doi: 10.1021/ml400137s. eCollection 2013 Jun 13.
Ref 5 Roles of the m(6)A Modification of RNA in the Glioblastoma Microenvironment as Revealed by Single-Cell Analyses. Front Immunol. 2022 Apr 26;13:798583. doi: 10.3389/fimmu.2022.798583. eCollection 2022.
Ref 6 Clinical pipeline report, company report or official report of Splash Pharmaceuticals.
Ref 7 UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. doi: 10.1093/jnci/88.14.956.
Ref 8 Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015 Mar 30;6:135. doi: 10.3389/fimmu.2015.00135. eCollection 2015.
Ref 9 A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. doi: 10.1158/1078-0432.CCR-06-0910.
Ref 10 Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. doi: 10.1016/s0968-0896(03)00191-3.
Ref 11 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 13 Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. doi: 10.1158/1078-0432.CCR-20-3716. Epub 2021 Jan 13.
Ref 14 Clinical pipeline report, company report or official report of Symphogen.
Ref 15 Clinical pipeline report, company report or official report of BeiGene.
Ref 16 Clinical pipeline report, company report or official report of Agenus.
Ref 17 Influence of N6-Methyladenosine Modification Gene HNRNPC on Cell Phenotype in Parkinson's Disease. Parkinsons Dis. 2021 Dec 20;2021:9919129. doi: 10.1155/2021/9919129. eCollection 2021.
Ref 18 Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. doi: 10.1021/jm051101g.
Ref 19 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. doi: 10.1038/nrd4545.
Ref 20 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
Ref 21 The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med. 2014 Feb;2(2):98-107. doi: 10.1016/S2213-2600(13)70259-5. Epub 2013 Dec 23.
Ref 22 Pegylated interferon Beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.
Ref 23 Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62. doi: 10.2165/00023210-200923060-00001.
Ref 24 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 25 PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138.
Ref 26 Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65. doi: 10.1111/j.1349-7006.2004.tb02194.x.
Ref 27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032947)
Ref 29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 728).
Ref 30 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. doi: 10.1182/blood-2005-06-2317. Epub 2005 Oct 27.
Ref 31 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 32 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.
Ref 33 Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31.
Ref 34 CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94.
Ref 35 CD45 / PTPRC Antibody, Biotin conjugate (OX-30).
Ref 36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932)
Ref 37 US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.
Ref 38 Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94. doi: 10.1016/s0169-5002(01)00263-x.
Ref 39 Piperazine derivatives for treating disorders. US9695160.
Ref 40 Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population. Arch Toxicol. 2021 Jan;95(1):299-309. doi: 10.1007/s00204-020-02911-2. Epub 2020 Sep 22.
Ref 41 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. doi: 10.1016/j.drudis.2020.04.023. Epub 2020 May 7.
Ref 42 A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3. doi: 10.1016/j.bmcl.2007.05.088. Epub 2007 Jun 3.